Bellicum Pharmaceuticals, Inc. today announced that four abstracts, including an oral presentation on the Company’s lead product candidate BPX-501, were accepted for presentation at the 59th American Society of Hematology (ASH) Annual Meeting.
Bellicum Pharmaceuticals, Inc. today announced that four abstracts, including an oral presentation on the Company’s lead product candidate BPX-501, were accepted for presentation at the 59th American Society of Hematology (ASH) Annual Meeting.